Caplight Directory>Companies>Iolyx Therapeutics-preview>Iolyx-therapeutics


Iolyx Therapeutics

Iolyx Therapeutics

Private
Burlingame, CaliforniaHealthcare & Life Scienceswww.iolyx.com

Last Round

Series B

Dec 3, 2025

Total Funding Raised

$45M

Company Overview

Iolyx Therapeutics is a biotechnology company focused on developing innovative therapies for ocular diseases through advanced immunology and ophthalmology solutions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

ocular inflammationophthalmology drugsclinical-stage biotechdry eye diseaseage-related macular degenerationAMDdiabetic retinopathytargeted therapiesocular drug deliveryimmunomodulatory therapysteroid-sparing therapydrug developmentbiopharmauveitis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Iolyx Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Iolyx Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BDec 3, 2025
Series AApr 20, 2023
View all Funding Rounds

Iolyx Therapeutics Investors

Notable investors and investment history

InvestorRounds
Frazier Healthcare PartnersSeries A
Frazier Life SciencesSeries B
Alumni VenturesSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 3, 2025

    $15M round completed.

  • Dec 3, 2025

    Partnering with Laboratoires Théa for autoimmune dry eye treatment.

View all signals

Iolyx Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Iolyx Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Iolyx Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlingame, California
Employee Range10
Year Founded2019
Last FundingDec 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.